The office building of biopharmaceutical company AstraZeneca is being seen in Shanghai, China, on May 23, 2024. A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest healthcare news straight to your inbox. Subscribe here to receive future editions. AstraZeneca said it is doubling down on its investment in its U.S. business, a move that comes just one week after Donald Trump's election win. AstraZeneca announced plans for $2 billion in new spending on research ...

AstraZeneca's (AZN) third-quarter 2024 core earnings of $1.04 per American depositary share (ADS) beat the Zacks Consensus Estimate of $1.01 per share. Core earnings of $2.08 per share fell 20% year over year on a reported basis and 27% at constant exchange rates (CER). Total revenues of $13.57 billion rose 18% on a reported basis and 21% at CER, driven by higher product sales and alliance revenues from partnered medicines. Revenues also beat the Zacks Consensus Estimate of $13.04 billion. All growth rates ...

9M and Q3 2024 Results Conference call and webcast for investors and analysts 12 November 2024 Forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter 'the Group') provides the following cautionary statement: This document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, stateme ...

AstraZeneca PLC (NASDAQ:AZN) Q3 2024 Earnings Conference Call November 12, 2024 9:00 AM ET Company Participants Andy Barnett - Head, Investor Relations Pascal Soriot - Executive Director and CEO Aradhana Sarin - Executive Director and CFO Dave Fredrickson - Executive Vice President, Oncology Business Susan Galbraith - Executive Vice President, Oncology Research and Development Ruud Dobber - Executive Vice President and President, BioPharmaceuticals Sharon Barr - Executive Vice President, BioPharmaceuticals ...

Astrazeneca (AZN) reported $13.57 billion in revenue for the quarter ended September 2024, representing a year-over-year increase of 18%. EPS of $1.04 for the same period compares to $0.87 a year ago.The reported revenue represents a surprise of +4.02% over the Zacks Consensus Estimate of $13.04 billion. With the consensus EPS estimate being $1.01, the EPS surprise was +2.97%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Stre ...

Company Performance - AstraZeneca increased its full-year sales outlook due to booming demand for its cancer and rare-disease drugs [1][2] - The company now projects fiscal 2024 revenue and core EPS to grow by a high-teens percentage, up from a mid-teens percentage [2] - AstraZeneca reported higher-than-estimated Q3 results with revenue of $13.57 billion, up from $11.49 billion last year, and core EPS of $2.08, beating estimates of $2.06 [4] Investment Plans - AstraZeneca plans to invest $3.5 billion in its U.S. business by the end of 2026, including $2 billion to create more than a thousand new high-skilled jobs [1][3] - The investment will expand the company's U.S. research and manufacturing footprint, including an R&D center in Cambridge, Mass., a biologics manufacturing facility in Maryland, specialty manufacturing in Texas, and cell therapy manufacturing capacity on the West and East Coasts [3] Market and Demand - The company's strong growth trajectory in the first nine months of 2024 reflects growing demand for medicines across oncology, biopharmaceuticals, and rare disease [3] Legal and Regulatory - AstraZeneca has not received any notification that it is under investigation in China despite senior executives being implicated in an insurance fraud case [5]

Aykut Karahan | Istock | Getty Images A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest healthcare news straight to your inbox. Subscribe here to receive future editions. Happy Friday! Buried in the election news this week was new data from drugmakers vying to enter the booming weight loss drug market. Pharmaceutical giant AstraZeneca and biotech company Viking Therapeutics were among the companies that presented encouraging data on their obesity pills an ...

The latest trading session saw Astrazeneca (AZN) ending at $64.69, denoting a +1.32% adjustment from its last day's close. The stock outpaced the S&P 500's daily gain of 0.74%.The the stock of pharmaceutical has fallen by 17.62% in the past month, lagging the Medical sector's loss of 2.99% and the S&P 500's gain of 3.16%.Analysts and investors alike will be keeping a close eye on the performance of Astrazeneca in its upcoming earnings disclosure. The company's earnings report is set to go public on November ...

When I last wrote about the Anglo-Swedish pharmaceuticals company AstraZeneca (NASDAQ: AZN ) in June, further upside to the stock was already unlikely. This prompted a Hold rating on it, breaking the trend from the previous seven Buy ratings on it since 2022. This Manika is a macroeconomist with over 20 years of experience in industries including investment management, stock broking, investment banking. She also runs the profile Long Term Tips [LTT], which focuses on the generational opportunity in the gree ...

Wall Street analysts expect Astrazeneca (AZN) to post quarterly earnings of $1.01 per share in its upcoming report, which indicates a year-over-year increase of 16.1%. Revenues are expected to be $13.04 billion, up 13.5% from the year-ago quarter. The consensus EPS estimate for the quarter has undergone a downward revision of 0.2% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe. Before ...